Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Splenomegaly 1Primary Myelofibrosis 1Neoplasm Metastasis 1Melanoma 1Leukemia 1Epidermolysis Bullosa Dystrophica 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Anemia 1Adenocarcinoma 1

Interventions

Oxaliplatin 32Fluorouracil 24Gemcitabine 23Leucovorin 19Docetaxel 19pembrolizumab 17Capecitabine 15Radiotherapy 14Irinotecan 13Cisplatin 11Bevacizumab 11Nivolumab 8130-nm albumin-bound paclitaxel 8Trastuzumab 7Erlotinib Hydrochloride 7Cyclophosphamide 7Albumin-Bound Paclitaxel 7Radiosurgery 6Paclitaxel 6Taxes 5S 1 (combination) 5Metformin 5Carboplatin 5Blood Specimen Collection 5Sunitinib 4Sorafenib 4Pemetrexed 4Esophagectomy 4Chemoradiotherapy 4Cetuximab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma × ON 01910 × Clear all
NCT04263090 2024-05-09

Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
25 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡